Navigation Links
Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010
Date:9/13/2010

tts General Hospital and the Dana-Farber Cancer Institute. In this study Pharmacyclics' HDAC Inhibitor is being administered in combination with doxorubicin.  To date 8 patients enrolled in this study and 3 have reported at least stable disease. Currently, 4 patients are on treatment, 2 of which have completed 4 cycles of treatment.  These early results are considered encouraging in this deadly and rapidly progressing disease, which represents a serious unmet medical need.
  • Histone deacetylase 8 (HDAC 8) Inhibitor Program, is currently in the preclinical lead optimization stage. The company is on track to conclude its lead optimization work by the end of calendar year 2010.

  • Conference Call and Webcast DetailsThe Company will hold a conference call today at 4:30 p.m. EDT to discuss fiscal 2010 year-end financial results and achievements and fiscal 2011 guidance. To participate in the conference call, please dial 1-877-407-8133 for domestic callers and 1-201-689-8040 for international callers.  To access the live audio broadcast or the subsequent archived recording, log on to http://ir.pharmacyclics.com/events.cfm. The archived version of the webcast will be available on the company's website for 1 month.

    Use of Non-GAAP Financial MeasuresThis press release contains non-GAAP financial measures, and includes operating and other expenses adjusted to exclude certain non-cash and non-recurring expenses. These measures are not in accordance with, or an alternative for generally accepted accounting principles, or GAAP, and may be different from non-GAAP financial measures used by other companies. Among the items included in GAAP presentations but excluded for purposes of determining non-GAAP financial measures that we present are: non-cash interest expense associated with the loan from an affiliate of Robert W. Duggan; employee related non-cash expenses; the withholdi
    '/>"/>

    SOURCE Pharmacyclics
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related medicine technology :

    1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
    2. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
    3. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
    4. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
    5. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
    6. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
    7. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
    8. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
    9. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
    10. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
    11. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/14/2014)... (Nasdaq: LMNX ) today announced that it expects ... Monday, February 3, 2014. A press release announcing the results ... (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) Management will ... financial results for the fourth quarter and twelve months ended ...
    (Date:1/14/2014)... , Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s new SLIC ... guide with accompanying instrumentation to place and insert the ... the soft tissue (e.g. ligament) repair or reconstruction as ... heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ...
    (Date:1/14/2014)... , Jan. 14, 2014   Oligomerix, Inc. , a ... therapeutics for Alzheimer,s disease (AD) and related neurodegenerative disorders, ... Valhalla, NY as of January ... space at New York Medical College. Oligomerix, ...
    Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
    ... 21, 2011 MicroAire Surgical Instruments ... for carpal tunnel syndrome.  MicroAire,s new device, called ... assembly that allows surgeons to treat carpal tunnel ... wrist – thereby avoiding full open-hand surgery through ...
    ... 2011 Seal Shield LLC today announced ... for the iPad.  The product has been designed specifically ... use in hospital settings. The Seal Shield ... which is resistant to liquids including blood and bleach. ...
    Cached Medicine Technology:MicroAire Introduces New SlimLine™ ECTR Cannula 2
    (Date:4/22/2014)... 2014) The International Communication Association will hold ... Washington. The theme of the 2014 conference will ... networked and digital society. , Featuring over 2,300 ... 2,200 Communication scholars representing over 40 countries, the ... conference in the world. This year,s conference features ...
    (Date:4/22/2014)... 22, 2014Hemoglobin A1c is the standard measurement for assessing ... levels of A1c are typically measured every few months ... data-based model that accurately estimates A1c using self-monitored blood ... & Therapeutics ( DTT ), a peer-reviewed journal ... available free on the DTT website at ...
    (Date:4/22/2014)... April 2014. The latest scientific advances and emerging therapies ... 2014, the main annual meeting of the Heart Failure ... Journalists will also hear breaking news on acute heart ... Failure, which is part of the main congress. , ... Greece, at the Megaron Athens International Conference Centre (MAICC). ...
    (Date:4/22/2014)... at the University of Utah (U of U) has ... separate cases, U of U researchers and their colleagues ... Journal of Human Genetics . The software, Phevor (Phenotype ... unknown gene mutations by analyzing the exomes, or areas ... made, in individual patients and small families. , ...
    (Date:4/22/2014)... Nearly 7 in 10 Americans support mandated coverage of ... by researchers at the University of Michigan Health System. ... age of 18 at home, and adults with private ... adults to support universal coverage of birth control medications, ... Journal of the American Medical Association ( JAMA ...
    Breaking Medicine News(10 mins):Health News:International Communication Association to hold Annual Conference in Seattle, Washington 2Health News:The world's largest heart failure congress 2Health News:The world's largest heart failure congress 3Health News:Applying math to biology: Software identifies disease-causing mutations in undiagnosed illnesses 2Health News:Applying math to biology: Software identifies disease-causing mutations in undiagnosed illnesses 3Health News:More than two-thirds of Americans support mandated coverage of birth control in health plans 2
    ... BOULDER, Colo., Aug. 25 Bioelements has ... www.ro o m214.com ) to support research, ... and online initiatives. "Room 214 was chosen as our ... consumer behavior," said Callie Lushina, Vice President of Marketing for ...
    ... , , Says Damage ... , , WASHINGTON, Aug. 25 The ... ) board to remove CEO John Mackey as Chairman and to begin ... Foods, lead independent director, Dr. John Elstrott, yesterday afternoon. Citing the ...
    ... ... across the nation take a collective step to improve their health through exercise and increased ... that may unlock the secret to living longer and healthier lives. , ... Cambridge, MA (Vocus) August 25, 2009 -- This ...
    ... CINCINNATI, Aug. 25 HealthWarehouse.com, Inc. (OTC Bulletin Board: ... financial results for the second quarter ended June 30, 2009. ... heavy growth in prescription sales and pharmacy transfers. Gross margins ... quarter was $396,271. , , "Consumers are ...
    ... , LOUISVILLE, Colo., Aug. 25 According ... Reconstructive Surgery Journal , the official journal of the American ... to be a safe and effective treatment option for fat ... Lipo to be an enhanced fat removal and transfer system ...
    ... in unpasteurised food has been detected in unusually high ... with the condition pre-eclampsia. These results are important ... indicator of pre-eclampsia and may help scientists to understand ... Scientists at the University of Leeds took blood ...
    Cached Medicine News:Health News:Bioelements Selects Room 214 as Their Social Media and Online Marketing Agency 2Health News:CtW Investment Group Calls for Whole Foods Board to Remove Chair and CEO John Mackey 2Health News:CtW Investment Group Calls for Whole Foods Board to Remove Chair and CEO John Mackey 3Health News:CtW Investment Group Calls for Whole Foods Board to Remove Chair and CEO John Mackey 4Health News:Aging Science Leaders to Gather During Active Aging Week to Encourage Discovery in Healthy Living and Longevity 2Health News:Aging Science Leaders to Gather During Active Aging Week to Encourage Discovery in Healthy Living and Longevity 3Health News:HealthWarehouse.com, Inc. Announces Second Quarter Financial Results; Revenues Increase Significantly Over Second Quarter 2008 2Health News:HealthWarehouse.com, Inc. Announces Second Quarter Financial Results; Revenues Increase Significantly Over Second Quarter 2008 3Health News:New Study Reveals VASER(R) Lipo to be the New Standard of Care for Body Contouring and Fat Transfer Procedures 2Health News:New Study Reveals VASER(R) Lipo to be the New Standard of Care for Body Contouring and Fat Transfer Procedures 3Health News:New link between pre-eclampsia and diet 2
    ... time-consuming tasks and delivers consistently ... productivity and ensure testing accuracy ... offers automated reticulocyte counts and ... excellent sensitivity, specificity and efficiency ...
    The Fathom Guidewire combines a nitinol hypotube distal segment with advanced microfabrication technology, creating a design that revolutionizes access of the most tortuous vasculature....
    ... bi-polar CryoCor CryoBlator Series of Cryoablation Catheters ... catheter design with the two-stage cooling system ... maximize the delivery of cryoenergy to the ... work together to create the transmural lesions ...
    ... 5 software, the latest from Quality ... management application designed specifically for implementing ... system. The superior design, functionality, security, ... tool for managing a quality program., ...
    Medicine Products: